LOS ANGELES, CA / ACCESSWIRE / October 31, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against MGT Capital Investments, Inc. (“MGT” or the “Company”) (NYSE MKT: MGT) concerning possible violations of federal securities laws between May 9, 2016 and September 20, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm before the November 21, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that MGT made false and/or misleading statements and/or failed to disclose the risk that its stock to be issued in connection with the acquisitions of D-Vasive and Demonsaw may not be listed by the New York Stock Exchange (“NYSE”); and that MGT was under inquiry by the U.S. Securities and Exchange Commission (“SEC”) prior to September 19, 2016. On September 19, 2016, the Company announced that it received a subpoena from the SEC requesting information, and that it received a notification from the NYSE that the exchange would not approve the listing of the 43.8 million shares MGT is required to issue in order to complete the D-Vasive merger. When this news went public, MGT’s stock price fell.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 447991

IRVINE, CA / ACCESSWIRE / October 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Seres Therapeutics (“Seres” or the “Company”) (Nasdaq: MCRB). Investors who purchased or otherwise acquired shares between June 25, 2015 and July 29, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the November 28, 2016 lead plaintiff motion deadline.

If you purchased Seres shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that throughout the Class Period, Seres made materially false and misleading statements and/or failed to disclose material facts about its lead drug product candidate SER-109, praising its potential and efficacy. On July 29, 2016, the Company announced that the Phase 2 clinical trial of SER-109 did not meet its primary endpoint. When this news emerged to the public, the stock price of Seres declined, causing investors harm.

If you wish to learn more about this lawsuit free of charge, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 447990

IRVINE, CA / ACCESSWIRE / October 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action against Ferrellgas Partners LP (“Ferrellgas” or the “Company”) (NYSE: FGP). Investors who purchased or otherwise acquired shares between June 1, 2015 and September 28, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm by the December 5, 2016 lead plaintiff motion deadline.

If you purchased Ferrellgas shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Ferrellgas made false and/or misleading statements and/or failed to disclose: that its propane sales were declining; that the Company’s midstream logistics business was being negatively affected by lower crude oil prices; that Ferrellgas’ Adjusted EBITDA would fall below its projections; that the Company was becoming increasingly leveraged and would need to obtain an amendment under the secured credit facility and accounts receivable securitization facility to increase the maximum leverage ratio to a range of 5.95x – 6.05x; that Ferrellgas would likely need to reduce its dividend; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

On September 28, 2016, Ferrellgas announced that had a net loss for fiscal 2016 of approximately $665 million, whereas it had a net profit of $29 million for fiscal 2015. Also, the Company’s President, CEO and Director Stephen Warnbold resigned immediately. When this information became public, Ferrellgas’ stock price decreased.

If you wish to learn more about this lawsuit at no cost to you, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 447986

IRVINE, CA / ACCESSWIRE / October 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against National Beverage Corp. (“National Beverage” or the “Company”) (Nasdaq: FIZZ). Investors who purchased or otherwise acquired National Beverage shares between July 16, 2015 and September 28, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the December 5, 2016 lead plaintiff motion deadline.

If you purchased shares of National Beverage during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, National Beverage made false and misleading statements and/or failed to disclose that it lacked effective internal controls over financial reporting. On September 27, 2016, Glaucus Research Group published a report revealing: that National Beverage’s former CEO and Chairman admitted to manipulating the Company’s earnings and directing his son to make fake invoices; that the Company refused to allow a potential acquirer to perform adequate due diligence which led to the failure of a significant transaction; that National Beverage officers are compensated by a privately held company which disallows shareholder visibility; that the Company’s former counsel testified that he and former general counsel “fudged facts” on the Company’s behalf in a previous litigation; and that gifts of stock were not disclosed in the Company’s SEC filings. Thus, the Company’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to learn more about this lawsuit at no charge, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 447989

LOS ANGELES, CA / ACCESSWIRE / October 31, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit has been filed against Taro Pharmaceutical Industries (“Taro” or the “Company”) (NYSE: TARO) concerning possible violations of federal securities laws between July 3, 2014 and September 9, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm prior to the December 27, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, Taro made false and/or misleading statements and/or failed to disclose that: since 2014 the Company has worked with other pharmaceutical companies to keep the price of generic products artificially high; that the foregoing behavior violated federal antitrust laws; that Taro’s revenues during the Class Period were the result of illegal conduct; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On September 9, 2016, the Company announced that its subsidiary and two senior officers received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, seeking documents regarding the sale of generic pharmaceutical products. Then on October 17, 2016, NECA-IBEW Welfare Trust Fund filed an antitrust class action lawsuit against Taro and several other pharmaceutical companies alleging involvement in the price-fixing of Clobetasol since 2014.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 447985

LOS ANGELES, CA / ACCESSWIRE / October 31, 2016 / Lundin Law PC, a shareholder rights firms, announces a class action lawsuit has been filed against Xerox Corporation (“Xerox” or the “Company”) (NYSE: XRX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired shares between April 23, 2012 and October 23, 2015 (the “Class Period”), are encouraged to contact the firm before the December 23, 2016
lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Xerox repeatedly touted its new software product, Health Enterprise, as an important growth area for the Company, which would operate at low cost and high profit margin. The Company’s statements pertaining to the profitability and growth prospects of the Health Enterprise business were materially false and misleading because Xerox failed to disclose: that the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; that Xerox would be unable to deliver Health Enterprise implementations at sustainable profits; and that as a result of the above, the Company’s statements about its business, operations, and prospects lacked a reasonable basis.

On October 26, 2015, Xerox released its third quarter 2015 financial results which were disappointing due to costs associated with the implementation of Health Enterprise and the termination of Health Enterprise contracts with two state agencies.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 447983

NEW YORK, NY / ACCESSWIRE / October 31, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. (“American Renal Associates” or the “Company”) (NYSE: ARA) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased American Renal Associates securities: (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ara or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in American Renal Associates you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 448005

NEW YORK, NY / ACCESSWIRE / October 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Level 3 Communications, Inc. (NYSE: LVLT) stock prior to October 31, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Level 3 to CenturyLink (NYSE: CTL). Under the terms of the transaction, Level 3 shareholders will receive $26.50 in cash and 1.4286 shares of CenturyLink for each share of Level 3 stock they own; this represents a total approximate value of $66.50 per share. To learn more about the action and your rights, go to:

http://zlk.9nl.com/level3-lvlt

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 448006

NEW YORK, NY / ACCESSWIRE / October 31, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AECOM (“AECOM” or the “Company”) (NYSE: ACM) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased AECOM securities between February 11, 2015 and August 15, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

AECOM and its subsidiaries design, build, finance, and operate infrastructure assets worldwide. On October 17, 2014, AECOM announced that the Company had settled its acquisition of URS Corp. (“URS” and the “URS Acquisition”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) AECOM engaged in fraudulent and deceptive business practices (2) AECOM lacked effective internal controls over financial reporting; (3) AECOM overstated the benefits of the URS Acquisition; (4) AECOM overstated the Company’s free cash flow per share; and (5) consequently, AECOM’s public statements were materially false and misleading at all relevant times.

On August 16, 2016, Spruce Point Capital Management released an article about AECOM and wrote, “after a careful forensic financial and accounting analysis of AECOM’s recent financial results and condition, we believe that AECOM’s stock is worth approximately 33% – 45% less than its current price.” The Spruce Point Report also noted that there is “material weaknesses of internal controls over financial reporting associated with [the Company’s] acquisition of URS [Corp.]” and AECOM management’s “misaligned incentive structure,” pursuant to which the Company’s “CEO’s $18 million compensation in 2015 [was] heavily tied to its aggressive interpretation of its Free Cash Flow per share.” Following this news, AECOM stock dropped $1.65, or 4.7%, to close at $33.44 on August 16, 2016, damaging investors.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/acm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in AECOM you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 448004

LEXINGTON, KY / ACCESSWIRE / October 31, 2016 / The law firm of Mehr, Fairbanks & Peterson Trial Lawyers, PLLC is investigating potential breach of fiduciary duty claims against Spark Energy, Inc. (NASDAQ GS: SPKE) (“SPKE”).

Current SPKE shareholders who wish to discuss this investigation and their legal options are encouraged to contact Mehr, Fairbanks & Peterson Trial Lawyers, PLLC (Erik D. Peterson, Esq.) at (800) 249-3731 or via e-mail at contact@austinmehr.com. For additional information about this investigation, please visit www.mehrfairbanks.com/spark/.

The attorneys at Mehr, Fairbanks & Peterson, PLLC have broad experience representing shareholders and other consumers in trial and appellate courts nationwide. For more information about Mehr, Fairbanks & Peterson Trial Lawyers, PLLC, or for additional information about this investigation, please visit www.mehrfairbanks.com. This is an advertisement.

CONTACT:

Mehr, Fairbanks & Peterson Trial Lawyers, PLLC
Erik D. Peterson, Esq.
201 W. Short Street, STE 800
Lexington, KY 40502
1-800-249-3731 (toll free)
contact@austinmehr.com

SOURCE: Mehr, Fairbanks & Peterson Trial Lawyers, PLLC

ReleaseID: 448002